ly3556050
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Sep 14, 2016 (NCT05341102)
Timeline
Indications
Mechanism of action
- Somatostatin receptor 4INHIBITOR
SSTR4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06074562 | Phase 2 | Oct 5, 2023 | Eli Lilly |
| NCT06052462 | Phase 1 | Sep 20, 2023 | Eli Lilly |
| NCT05615467 | Phase 1 | Nov 15, 2022 | Eli Lilly |
| NCT04874636 | Phase 2 | May 20, 2021 | Eli Lilly |
| NCT04707157 | Phase 2 | May 6, 2021 | Eli Lilly |
| NCT04627038 | Phase 2 | Nov 12, 2020 | Eli Lilly |
| NCT05986292 | Phase 2 | Jan 30, 2020 | Eli Lilly |
| NCT04156750 | Phase 1 | Nov 20, 2019 | Eli Lilly |
| NCT05341102 | Phase 1 | Sep 14, 2016 | Eli Lilly |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 9 | 9 | 2 | 2016 |
1 organizations
Page 1 / 1